Lymphoma News Archive

Novel STAT3 Inhibitor Shows Some Anticancer Activity

Novel STAT3 Inhibitor Shows Some Anticancer Activity

Eighteen and 127 patients were enrolled into dose-escalation and dose expansion cohorts, respectively.

Long-Term Ibrutinib Yields Deep, Durable Responses in Chronic Lymphocytic Leukemia

Long-Term Ibrutinib Yields Deep, Durable Responses in Chronic Lymphocytic Leukemia

No PFS or OS events were reported for treatment-naive elderly patients.

Cognitive Impairment Worsens Survival Among Elderly Patients With Hematologic Cancer

Cognitive Impairment Worsens Survival Among Elderly Patients With Hematologic Cancer

A variety of cognitive impairments are common in the elderly US population, with as many as 14% of individuals over 70 being affected by dementia.

Ibrutinib With Lenalidomide, Rituximab Improves Response Rate in Relapsed or Refractory MCL

Ibrutinib With Lenalidomide, Rituximab Improves Response Rate in Relapsed or Refractory MCL

The most frequently reported grade 3 to 4 adverse events included neutropenia, infection, and cutaneous toxicity. Three treatment-related deaths (2 from sepsis and 1 from embolic stroke) were noted.

Pediatric Patients Hospitalized for Pneumonia May Have Elevated Cancer Risk

Pediatric Patients Hospitalized for Pneumonia May Have Elevated Cancer Risk

Short-term incidence of leukemia, lymphoma, and brain cancer may be higher in children who were hospitalized with pneumonia.

PET-driven Therapy Decisions Promising for Hodgkin Lymphoma

PET-driven Therapy Decisions Promising for Hodgkin Lymphoma

Patients treated with BEACOPP have improved outcomes compared with ABVD but also face significant adverse events. A major goal of therapy is therefore to minimize toxicity.

Rituximab Plus Bendamustine: Superior to R-CHOP for Grade 3A Follicular Lymphoma

Rituximab Plus Bendamustine: Superior to R-CHOP for Grade 3A Follicular Lymphoma

The median PFS was significantly longer in the R-B arm: 15.0 years compared with 11.7 years in the R-CHOP arm.

Age Alone Should Not Preclude Patients With Lymphoma From Undergoing ASCT

Age Alone Should Not Preclude Patients With Lymphoma From Undergoing ASCT

With improving supportive care, elderly patients may benefit from high-dose chemotherapy with autologous stem cell transplantation.

Brentuximab Vedotin Plus Bendamustine Safe, Effective as Second-line Hodgkin Lymphoma Treatment

Brentuximab Vedotin Plus Bendamustine Safe, Effective as Second-line Hodgkin Lymphoma Treatment

Patients who received the recommended phase 1 dose of brentuximab vedotin and bendamustine had an overall response of 78%.

Brentuximab Vedotin Plus Nivolumab May Be Effective Salvage Therapy for Hodgkin Lymphoma

Brentuximab Vedotin Plus Nivolumab May Be Effective Salvage Therapy for Hodgkin Lymphoma

Among the 60 evaluable patients, the objective response rate was 83%, with CR rate of 62%.

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, and Dacarbazine Prolongs PFS in Hodgkin Lymphoma

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, and Dacarbazine Prolongs PFS in Hodgkin Lymphoma

Researchers randomly assigned 1334 patients with untreated stage III or IV HL to receive A + AVD or ABVD for 6 cycles.

Acalabrutinib Yields Promising Response Rates in Relapsed/Refractory Mantle Cell Lymphoma

Acalabrutinib Yields Promising Response Rates in Relapsed/Refractory Mantle Cell Lymphoma

The median time to response (TRR) was 1.9 months. The median duration of response (DoR) was not reached, though the 12-month DoR rate was 72% (95% CI, 62-80%).

Predictors and Implications of Rituximab Maintenance Failure in Mantle Cell Lymphoma

Predictors and Implications of Rituximab Maintenance Failure in Mantle Cell Lymphoma

Patients who did not reach a first complete remission were twice as likely to fail rituximab maintenance therapy; patients who received autologous stem cell transplant had a decreased failure risk of 69%.

Ibrutinib Effective As First-line Therapy for Waldenstrom Macroglobulinemia

Ibrutinib Effective As First-line Therapy for Waldenstrom Macroglobulinemia

Ibrutinib is used among patients with WM who have previously received treatment, but its efficacy as a first-line therapy among treatment-naive patients is unknown.

Brentuximab Vedotin Effective in Adjusted Classical Hodgkin Lymphoma Regimen

Brentuximab Vedotin Effective in Adjusted Classical Hodgkin Lymphoma Regimen

The purpose of this study was to assess the benefit of brentuximab vedotin, an effective and well-tolerated agent for relapsed cHL, when added to standard eBEACOPP.

Brentuximab Vedotin Approved for Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-expressing Mycosis Fungoides

Brentuximab Vedotin Approved for Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-expressing Mycosis Fungoides

The U.S. Food and Drug Administration has approved brentuximab vedotin for the treatment of adult patients with pcALCL or CD30-expressing mycosis fungoides who have received prior systemic therapy.

Nivolumab Provides Long-term Benefit after Auto-HCT Classical Hodgkin Lymphoma

Nivolumab Provides Long-term Benefit after Auto-HCT Classical Hodgkin Lymphoma

An interim analysis of a cohort in the CheckMate-205 study showed that nivolumab had an acceptable safety profile and demonstrated efficacy among patients with relapsed and refractory classical Hodgkin lymphoma after post-auto-HCT brentuximab vedotin.

R-CHOP, R-CVP Confer Favorable Outcomes in Follicular Lymphoma

R-CHOP, R-CVP Confer Favorable Outcomes in Follicular Lymphoma

The open-label, multicenter, phase 3 FOLL05 trial included untreated patients with grade 1, 2, or 3a and Ann Arbor stage II to IV disease. This analysis included 504 evaluable patients.

FDA Grants Accelerated Approval to Acalabrutinib for Mantle Cell Lymphoma

FDA Grants Accelerated Approval to Acalabrutinib for Mantle Cell Lymphoma

The FDA based its approval on evidence from the single-arm, LY-004 clinical study, for which researchers enrolled 124 patients with MCL to receive acalabrutinib 100 mg twice daily.

EFS May Be A Surrogate for Overall Survival in Peripheral T Cell Lymphomas

EFS May Be A Surrogate for Overall Survival in Peripheral T Cell Lymphomas

Previous study suggests that EFS is a prognostically relevant variable among patients with other lymphomas; for this study, researchers evaluated whether EFS24 predicts for overall survival in PTCL.

FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma, Questions Remain About Cost and Toxicity

FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma, Questions Remain About Cost and Toxicity

Despite high efficacy, the $373,000 list price from the drug's manufacturer may preclude some patients from receiving axicabtagene ciloleucel.

FDA Grants Breakthrough Therapy Designation to Brentuximab Vedotin for Hodgkin Lymphoma

FDA Grants Breakthrough Therapy Designation to Brentuximab Vedotin for Hodgkin Lymphoma

The FDA granted Breakthrough Therapy Designation to brentuximab vedotin plus chemotherapy as first-line therapy for advanced classical Hodgkin lymphoma.

FDA Grants Accelerated Approval to Copanlisib for Follicular Lymphoma

FDA Grants Accelerated Approval to Copanlisib for Follicular Lymphoma

The FDA granted accelerated approval to copanlisib for the treatment of adult patients with relapsed follicular lymphoma who have received at least 2 prior treatments.

Biosimilar and Reference Rituximab May Have Similar ORR in Follicular Lymphoma

Biosimilar and Reference Rituximab May Have Similar ORR in Follicular Lymphoma

Patients with untreated FL were randomly assigned to receive cyclophosphamide, vincristine, and prednisone (CVP) plus rituximab (R) or GP2013 for 8 cycles followed by 2 years of monotherapy maintenance in patients who responded to treatment.

Transplantations May Have Similar Outcomes in Hodgkin's Lymphoma Regardless of Origin

Transplantations May Have Similar Outcomes in Hodgkin's Lymphoma Regardless of Origin

Researchers evaluated the outcomes of patients with HL who received HAPLO, SIB, or MUD transplantations.

FDA Grants Priority Review to Brentuximab sBLA for Cutaneous T Cell Lymphoma

FDA Grants Priority Review to Brentuximab sBLA for Cutaneous T Cell Lymphoma

At the median follow-up 22.9 months, 56.3% of patients in the BV arm achieved a significantly superior objective global response lasting at least 4 months vs 12.5% of patients in the IC arms.

Obinutuzumab Plus CHOP Does Not Prolong PFS in DLBCL

Obinutuzumab Plus CHOP Does Not Prolong PFS in DLBCL

Researchers enrolled 1418 patients with previously untreated DLBCL and randomly assigned them to receive G-CHOP or R-CHOP.

Dexamethasone, Rituximab, and Cyclophosphamide Effective in Waldenström Macroglobulinemia

Dexamethasone, Rituximab, and Cyclophosphamide Effective in Waldenström Macroglobulinemia

In patients with R/R WM, the overall response rate was 87%, with 4% of patients achieving a very good partial response.

Higher Opioid Prescription Rates Among Survivors of Cancer

Higher Opioid Prescription Rates Among Survivors of Cancer

Researchers enrolled 17,202 individuals, half of whom were cancer survivors and half of whom were healthy controls, to compare opioid prescription rates between the 2 groups.

Histological Transformation: A Key Predictor of Outcomes in Follicular Lymphoma

Histological Transformation: A Key Predictor of Outcomes in Follicular Lymphoma

Researchers enrolled patients with FL to investigate the cumulative incidence of HT, risk factors associated with HT, and the role of treatment and response on survival following transformation.

Mantle Cell Lymphoma: FDA Grants Breakthrough Therapy Designation to Acalabrutinib

Mantle Cell Lymphoma: FDA Grants Breakthrough Therapy Designation to Acalabrutinib

The FDA granted Breakthrough Therapy Designation to acalabrutinib for patients with MCL who have received at least 1 line of therapy.

Lenalidomide Maintenance May Prolong Progression-free Survival in DLBCL

Lenalidomide Maintenance May Prolong Progression-free Survival in DLBCL

The phase 3 REMARC study enrolled 650 treatment-naive patients with DLBCL or other aggressive B cell lymphomas.

Concordant Bone Marrow Involvement May Lead to Worse Outcomes in DLBCL

Concordant Bone Marrow Involvement May Lead to Worse Outcomes in DLBCL

Concordant BM involvement in patients diagnosed with diffuse large B cell lymphoma is associated with worse clinical outcomes.

FDA Approves Subcutaneous Rituximab and Hyaluronidase Human for Blood Cancers

FDA Approves Subcutaneous Rituximab and Hyaluronidase Human for Blood Cancers

The FDA granted approval to rituximab and hyaluronidase human as a subcutaneous injection for the treatment of follicular lymphoma, chronic lymphocytic leukemia, and DLBCL.

HBV Vaccine Can Prevent Non-Hodgkin Lymphoma in Adolescents

HBV Vaccine Can Prevent Non-Hodgkin Lymphoma in Adolescents

Universal vaccination against hepatitis B virus infection prevented non-Hodgkin lymphoma in adolescents in Taiwan, an endemic area for hepatitis B virus infection.

Prolonged PFS With Brentuximab Vedotin in Cutaneous T Cell Lymphoma

Prolonged PFS With Brentuximab Vedotin in Cutaneous T Cell Lymphoma

Brentuximab vedotin significantly prolonged PFS with higher response rates compared with methotrexate or bexarotene among patients with CTCL.

Rituximab for DLBCL May Double Risk of Subsequent AML

Rituximab for DLBCL May Double Risk of Subsequent AML

Rituximab's mechanism of action may reduce immune surveillance, allowing for the proliferation of cancer cells and infectious agents.

Young Patients With CLL At Risk for Secondary Cancers

Young Patients With CLL At Risk for Secondary Cancers

Patients with chronic lymphocytic leukemia younger than age 55 are at an increased risk for multiple types of secondary cancers for up to 15 years after diagnosis.

Ibrutinib Provides Long-term Benefits for Patients With CLL

Ibrutinib Provides Long-term Benefits for Patients With CLL

Ibrutinib provides long term survival benefits to patients with chronic lymphocytic leukemia regardless of cytogenetic risk factors.

Durable PFS With Fludarabine, Rituximab, and Lenalidomide in CLL

Durable PFS With Fludarabine, Rituximab, and Lenalidomide in CLL

Fludarabine and rituximab plus lenalidomide results in durable prolonged PFS compared with FR or FR plus cyclophosphamide among patients with untreated chronic lymphocytic leukemia.

Factors Associated With Hospice Enrollment Among Patients With Hematologic Cancers

Factors Associated With Hospice Enrollment Among Patients With Hematologic Cancers

Availability of important services and adequacy of care are among the factors explaining low numbers of patients with hematologic cancers being referred for hospice care.

Patients With DLBCL at Elevated Risk of Non-cancer-related Death

Patients With DLBCL at Elevated Risk of Non-cancer-related Death

Patients with DLBCL were at an increased risk of non-cancer-related deaths from blood disease, infection, gastrointestinal disease, vascular diseases, and lung disease.

Similar Efficacy and Safety With Subcutaneous Rituximab in Follicular Lymphoma

Similar Efficacy and Safety With Subcutaneous Rituximab in Follicular Lymphoma

Subcutaneous rituximab has similar efficacy and safety as the intravenous formulation for the first-line treatment of follicular lymphoma.

Pembrolizumab Effective Regardless of Prior Therapy in Classical Hodgkin Lymphoma

Pembrolizumab Effective Regardless of Prior Therapy in Classical Hodgkin Lymphoma

Pembrolizumab treatment resulted in high ORRs among patients with relapsed/refractory classic Hodgkin lymphoma regardless of previous therapy.

TET2 Loss May Indirectly Cause Hematologic Oncogenesis

TET2 Loss May Indirectly Cause Hematologic Oncogenesis

TET2 loss may indirectly cause several hematologic malignancies, including myeloid, T cell, and B cell cancers.

Lenalidomide Prolongs PFS Among Elderly Patients With DLBCL

Lenalidomide Prolongs PFS Among Elderly Patients With DLBCL

Data suggest that lenalidomide maintenance for 24 months can prolong PFS among elderly patients with DLBCL, but does not improve overall survival.

Single-nucleotide Polymorphisms Predict Response to R-CHOP in DLBCL

Single-nucleotide Polymorphisms Predict Response to R-CHOP in DLBCL

Two SNPS (rs4880 and rs1870377) had an association with PFS among patients with DLBCL receiving R-CHOP.

Steroid-containing Chemotherapy Can Induce Diabetes in DLBCL

Steroid-containing Chemotherapy Can Induce Diabetes in DLBCL

Glucocorticoid-containing chemotherapy may induce diabetes mellitus or worsen glucose control among patients with diffuse large B cell lymphoma.

Hodgkin Lymphoma Survivors at Risk for Second Cancers

Hodgkin Lymphoma Survivors at Risk for Second Cancers

Survivors with a family history of colorectal, breast, and lung cancer were at a significantly higher risk of similar second cancers.

Hodgkin Lymphoma: Nivolumab Active After Allogeneic HCT

Hodgkin Lymphoma: Nivolumab Active After Allogeneic HCT

PD-1 blockade with nivolumab was active in patients with Hodgkin lymphoma who received allogeneic hematopoietic cell transplantation.

Hodgkin Lymphoma: Intensifying Treatment With Rituximab After PET

Hodgkin Lymphoma: Intensifying Treatment With Rituximab After PET

Adjusting treatment dose after 2 courses of first-line therapy based on a positive PET scan does not improve progression-free survival.

Hodgkin Lymphoma Survivors Treated With Anthracyclines Have 3-fold Risk of Heart Failure

Hodgkin Lymphoma Survivors Treated With Anthracyclines Have 3-fold Risk of Heart Failure

Treatment with anthracyclines increases the risk for developing heart failure by 3-fold independently of radiation dose among survivors of Hodgkin lymphoma.

FDA Approves Ibrutinib for Rare Type of NHL

FDA Approves Ibrutinib for Rare Type of NHL

The FDA has granted accelerated approval to ibrutinib (Imbruvica) for the treatment of patients with relapsed/refractory marginal zone lymphoma.

Venetoclax is Well Tolerated, Active in Non-Hodgkin Lymphoma

Venetoclax is Well Tolerated, Active in Non-Hodgkin Lymphoma

Venetoclax was well-tolerated with variable efficacy against various non-Hodgkin lymphoma (NHL) subtypes.

Event-free Survival at 24 Months as a Surrogate Endpoint for DLBCL

Event-free Survival at 24 Months as a Surrogate Endpoint for DLBCL

Patients with diffuse large B-cell lymphoma (DLBCL) who achieved post-treatment event-free survival for 24 months had only a minimally lower life expectancy.

Allogeneic HSCT After PD-1 Blockade Appears Feasible in R/R Lymphoma

Allogeneic HSCT After PD-1 Blockade Appears Feasible in R/R Lymphoma

Allogeneic HSCT following treatment with an anti-PD-1 monoclonal antibody appears feasible in patients with relapsed/refractory lymphoma.

No Difference in Efficacy Between Ofatumumab, Rituximab in DLBCL

No Difference in Efficacy Between Ofatumumab, Rituximab in DLBCL

For relapsed or refractory diffuse large B-cell lymphoma (DLBCL), there is no difference in efficacy between ofatumumab or rituximab.

Thirty-month Complete Response in Follicular Lymphoma: A New Endpoint?

Thirty-month Complete Response in Follicular Lymphoma: A New Endpoint?

Thirty-month complete response is an accurate predictive endpoint for progression-free survival in follicular lymphoma clinical trials.

Rapid Rituximab Administration Safe for Primary CNS Lymphoma

Rapid Rituximab Administration Safe for Primary CNS Lymphoma

Rapid administration of rituximab over 90 minutes was safe and feasible for patients with primary central nervous system (CNS) lymphoma.

Radioimmunotherapy for DLBCL: Clinical Outcomes Post-R-CHOP

Radioimmunotherapy for DLBCL: Clinical Outcomes Post-R-CHOP

Elderly patients with diffuse large B-cell lymphoma ineligible for transplantation may benefit from radioimmunotherapy after chemoimmunotherapy.

Obinutuzumab-based Therapy Prolongs PFS in Untreated Follicular Lymphoma

Obinutuzumab-based Therapy Prolongs PFS in Untreated Follicular Lymphoma

Obinutuzumab-based induction and maintenance chemoimmunotherapy significantly improved progression-free survival.

Brentuximab Vedotin Superior to Standard of Care Options in CTCL

Brentuximab Vedotin Superior to Standard of Care Options in CTCL

Treatment with brentuximab vedotin is associated with superior clinical outcomes compared with standard of care options.

Chemo-free Induction Efficacious in Younger Patients With Mantle Cell Lymphoma

Chemo-free Induction Efficacious in Younger Patients With Mantle Cell Lymphoma

Chemotherapy-free induction with ibrutinib and rituximab is efficacious and well-tolerated among young patients.

Rituximab Maintenance Prolongs Survival Among Younger Patients With Mantle Cell Lymphoma

Rituximab Maintenance Prolongs Survival Among Younger Patients With Mantle Cell Lymphoma

Rituximab maintenance following autologous hematopoietic cell transplantation prolongs survival among younger patients with mantle cell lymphoma.

Brentuximab Vedotin + RCHP Active in High-intermediate/High Risk DLBCL

Brentuximab Vedotin + RCHP Active in High-intermediate/High Risk DLBCL

Brentuximab vedotin in combination with RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) is active as a frontline therapy.

Study Identifies Ultra-high Risk Category of Patients With DLBCL

Study Identifies Ultra-high Risk Category of Patients With DLBCL

Ultra-high risk category of patients with diffuse large B-cell lymphoma (DLBCL) who have dismal outcomes on existing therapies.

Clonal Hematopoiesis Increases Risk of Therapy-related Myeloid Malignancies

Clonal Hematopoiesis Increases Risk of Therapy-related Myeloid Malignancies

Clonal hematopoiesis at the time of primary cancer diagnosis was associated with a significantly increased risk of therapy-related myeloid neoplasm development.

FDA Grants Priority Review for Pembrolizumab in Treatment of Hodgkin Lymphoma

FDA Grants Priority Review for Pembrolizumab in Treatment of Hodgkin Lymphoma

The FDA has granted Priority Review to a sBLA that is seeking approval for pembrolizumab (Keytruda) for the treatment of Hodgkin lymphoma.

Lenalidomide Plus Rituximab Active in MALT Lymphoma

Lenalidomide Plus Rituximab Active in MALT Lymphoma

Lenalidomide plus rituximab may be more effective for the treatment of mucosa-associated lymphoid tissue lymphoma (MALT lymphoma).

Study Affirms Activity of Nivolumab in Heavily Pretreated Classical Hodgkin Lymphoma

Study Affirms Activity of Nivolumab in Heavily Pretreated Classical Hodgkin Lymphoma

Treatment with nivolumab (Opdivo) resulted in an encouraging response rate in an expanded population of patients with classical Hodgkin lymphoma.

Double-hit Lymphomas Linked to Inferior Outcomes After ASCT

Double-hit Lymphomas Linked to Inferior Outcomes After ASCT

Patients with double-hit lymphoma (DHL) or double-expressor lymphoma (DEL) have inferior outcomes following autologous stem cell transplantation (ASCT).

Enzyme Target May Be Effective Treatment for B-cell Lymphoma

Enzyme Target May Be Effective Treatment for B-cell Lymphoma

Targeting uracil-DNA glycosylase (UNG) may help to prevent the onset and proliferation of B-cell lymphoma.

Adding CVP ± Rituximab After IFRT Improves PFS vs IFRT Alone in Stage 1-2 Follicular Lymphoma

Adding CVP ± Rituximab After IFRT Improves PFS vs IFRT Alone in Stage 1-2 Follicular Lymphoma

Treatment with cyclophosphamide, vincristine, and prednisolone (CVP) significantly improved progression-free survival.

Lenalidomide Active in R/R Adult T-cell Leukemia/Lymphoma

Lenalidomide Active in R/R Adult T-cell Leukemia/Lymphoma

Lenalidomide induced clinically meaningful antitumor activity among patients with relapsed or recurrent aggressive adult T-cell leukemia/lymphoma (ATL).

Metabolic Tumor Volume Predicts Outcome in Follicular Lymphoma

Metabolic Tumor Volume Predicts Outcome in Follicular Lymphoma

Baseline total metabolic tumor volume is associated with treatment outcomes for patients with high-tumor-burden follicular lymphoma.

Trial of Brentuximab Vedotin in CD30+ CTCL Meets Primary End Point

Trial of Brentuximab Vedotin in CD30+ CTCL Meets Primary End Point

The phase 3 ALCANZA study evaluating brentuximab vedotin (Adcetris) met its primary endpoint.

Baseline Metabolic Tumor Volume Predicts Prognosis of Follicular Lymphoma

Baseline Metabolic Tumor Volume Predicts Prognosis of Follicular Lymphoma

Total metabolic tumor volume is effective for determining the prognosis of high-tumor-burden follicular lymphoma.

Higher CD4 Counts, Lower RNA Values Linked With Higher NHL, Sarcoma Incidence

Higher CD4 Counts, Lower RNA Values Linked With Higher NHL, Sarcoma Incidence

Non-Hodgkin lymphoma (NHL) and Kaposi's sarcoma may be more likely to occur in HIV-infected patients with higher CD4 counts and lower HIV RNA values.

Brentuximab Vedotin + AVD and ISRT Efficacious for Early Stage Hodgkin Lymphoma

Brentuximab Vedotin + AVD and ISRT Efficacious for Early Stage Hodgkin Lymphoma

Brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (AVD) followed by involved-site radiotherapy (ISRT) was efficacious.

Nivolumab Active After Both Auto-HSCT, Brentuximab Vedotin in Hodgkin Lymphoma

Nivolumab Active After Both Auto-HSCT, Brentuximab Vedotin in Hodgkin Lymphoma

Nivolumab induced frequent responses with an acceptable safety profile for patients with classical Hodgkin lymphoma.

GOYA Study of G-CHOP Fails to Meet Primary End Point

GOYA Study of G-CHOP Fails to Meet Primary End Point

The phase 3 GOYA study for patients with previously untreated diffuse large B-cell lymphoma (DLBCL) failed to meet its primary endpoint.

Bendamustine, Gemcitabine, Vinorelbine Promising Treatment for Relapsed or Refractory Hodgkin Lymphoma

Bendamustine, Gemcitabine, Vinorelbine Promising Treatment for Relapsed or Refractory Hodgkin Lymphoma

BeGEV appears to provide clinical benefit for patients with relapsed or refractory Hodgkin lymphoma, and ought to be developed further.

Adding Obinutuzumab to Bendamustine Clinically Beneficial for Patients With Rituximab-refractory NHL

Adding Obinutuzumab to Bendamustine Clinically Beneficial for Patients With Rituximab-refractory NHL

Obinutuzumab plus bendamustine followed by obinutuzumab maintenance significantly improved progression-free survival.

Patients With Hodgkin Lymphoma May Benefit From PET-CT Scans to Guide Treatment

Patients With Hodgkin Lymphoma May Benefit From PET-CT Scans to Guide Treatment

Patients with advanced Hodgkin lymphoma may benefit from positron-emission tomography-computed tomography (PET-CT) testing.

Adding Everolimus to R-CHOP Feasible for Diffuse Large B-cell Lymphoma

Adding Everolimus to R-CHOP Feasible for Diffuse Large B-cell Lymphoma

Everolimus administered for 14 days in combination with R-CHOP is feasible for the treatment of patients with diffuse large B-cell lymphoma (DLBCL).

Mogamulizumab May Be Effective for Aggressive R/R Adult T-cell Leukemia/Lymphoma

Mogamulizumab May Be Effective for Aggressive R/R Adult T-cell Leukemia/Lymphoma

Mogamulizumab induced an encouraging response rate in patients with relapsed/refractory adult T-cell leukemia/lymphoma.

Obinutuzumab Superior to Rituximab for Previously Untreated Follicular Lymphoma

Obinutuzumab Superior to Rituximab for Previously Untreated Follicular Lymphoma

Obinutuzumab was superior to rituximab with respect to progression-free survival in patients with previously untreated follicular lymphoma.

GnRHa Not Efficient In Preventing Premature Ovarian Failure in Lymphoma

GnRHa Not Efficient In Preventing Premature Ovarian Failure in Lymphoma

Gonadotropin-releasing hormone agonist (GnRHa) may not be efficient in preventing chemotherapy-induced premature ovarian failure (POF).

Nivolumab Approved for Classical Hodgkin Lymphoma

Nivolumab Approved for Classical Hodgkin Lymphoma

The FDA has granted accelerated approval to nivolumab (Opdivo) for the treatment of patients with classical Hodgkin lymphoma.

Panobinostat May Be Active in Select Patients With Refractory DLBCL

Panobinostat May Be Active in Select Patients With Refractory DLBCL

Among patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL), 28% of patients achieved a response with panobinostat.

CD CAR TCM Therapy Post-HSCT Feasible in Pts With B-cell NHL

CD CAR TCM Therapy Post-HSCT Feasible in Pts With B-cell NHL

Safety and feasibility of CD19 CAR TCM therapy post-myeloablative HSCT were established in non Hodgkin lymphoma.

ABVD, BEACOPP Demonstrate Similar Survival Advantage in Advanced-stage Hodgkin Lymphoma

ABVD, BEACOPP Demonstrate Similar Survival Advantage in Advanced-stage Hodgkin Lymphoma

ABVD and BEACOPP resulted in similar event-free survival and overall survival in patients with high-risk advanced-stage Hodgkin lymphoma.

Inotuzumab Ozogamicin Active in Heavily Pretreated Indolent B-cell NHL

Inotuzumab Ozogamicin Active in Heavily Pretreated Indolent B-cell NHL

Investigational antibody-drug conjugate shows significant activity in patients with indolent B-cell non-Hodgkin lymphoma, but safety concerns remain.

Adding Rituximab to Short Intensive Chemo Improves EFS in Burkitt Lymphoma

Adding Rituximab to Short Intensive Chemo Improves EFS in Burkitt Lymphoma

The addition of rituximab to a short intensive chemotherapy regimen improved event-free survival in adult patients with Burkitt lymphoma or leukemia.

Anti-CD19 CAR T-Cells Safe for Refractory Aggressive Non-Hodgkin Lymphoma

Anti-CD19 CAR T-Cells Safe for Refractory Aggressive Non-Hodgkin Lymphoma

Anti-CD19 chimeric antigen receptor (CAR) T-cells were determined to be safe for further study in patients with refractory aggressive non-Hodgkin lymphoma.

Decreasing Frequency of Romidepsin Infusions May Prolong Response

Decreasing Frequency of Romidepsin Infusions May Prolong Response

Decreasing the frequency of infusions of romidepsin in patients with cutaneous T-cell lymphoma who achieve a response may prolong response.

MATRix Regimen as New Standard for Primary CNS Lymphoma

MATRix Regimen as New Standard for Primary CNS Lymphoma

The MATRix regimen may be the new standard chemoimmunotherapy for the treatment of central nervous system (CNS) lymphoma.

Routine Bone Marrow Biopsy Does Not Provide Prognostic, Diagnostic Value Over PET/CT in Most With DLBCL

Routine Bone Marrow Biopsy Does Not Provide Prognostic, Diagnostic Value Over PET/CT in Most With DLBCL

Routine bone marrow biopsy (BMB) did not contribute relevant diagnostic or prognostic value over positron emission tomography (PET)/computed tomography (CT) alone.

Novel Dual HDAC/PI3K Inhibitor Assessed in Lymphoma, Myeloma

Novel Dual HDAC/PI3K Inhibitor Assessed in Lymphoma, Myeloma

CUDC-907 had an acceptable safety profile and demonstrated promising preliminary evidence of response in patients with diffuse large B-cell lymphoma.

Methotrexate, TMZ, and Rituximab Followed by hWBRT Safe for Patients With CNS Lymphoma

Methotrexate, TMZ, and Rituximab Followed by hWBRT Safe for Patients With CNS Lymphoma

Treatment of primary central nervous system lymphoma with methotrexate, TMZ, and rituximab, followed by hWBRT and subsequent TMZ was safe.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Cancer Therapy Advisor Articles